Sanofi SA
SNYNF
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Sanofi SA News & Analysis
markets
Globalisation declining? Not in investor portfolios
Morningstar Indexes through a geographic revenue lens.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,207.30 | 32.70 | -0.35% |
| CAC 40 | 7,683.85 | 159.19 | -2.03% |
| DAX 40 | 24,163.36 | 109.76 | -0.45% |
| Dow JONES (US) | 45,282.47 | 349.27 | -0.77% |
| FTSE 100 | 9,266.93 | 54.47 | -0.58% |
| HKSE | 25,524.92 | 304.99 | -1.18% |
| NASDAQ | 21,449.29 | 47.24 | -0.22% |
| Nikkei 225 | 42,394.40 | 413.42 | -0.97% |
| NZX 50 Index | 12,957.98 | 121.52 | -0.93% |
| S&P 500 | 6,439.32 | 27.59 | -0.43% |
| S&P/ASX 200 | 8,935.60 | 31.30 | -0.35% |
| SSE Composite Index | 3,868.38 | 15.18 | -0.39% |